Visit poster 86 today to find out about IgA and lupus at the #bsi2025 and talk to @clairebeesley.bsky.social

Just out! We challenge the prevailing caution and advocate for a biomarker-guided approach soon to be tested in the STRATIFY lupus trial: Rituximab–belimumab combination for refractory SLE @shipam.bsky.social @versusarthritis.bsky.social www.thelancet.com/journals/lan...

@arrdept-ucldom.bsky.social Just out! Our latest lupus paper shows IgA2⁺ B-cells & IgA2-anti-dsDNA Abs are selectively targeted doi.org/10.1016/j.xc... Builds on theranostic discovery doi.org/10.1016/S266... On BEAT-Lupus doi.org/10.7326/M21-... Lupus ≠ one-size-fits-all doi.org/10.1084/jem....

So fantastic to see this work out @shipam.bsky.social, with Prof Michael Ehrenstein and Dr Dan McCluskey. This new departmental paper shows the utility of anti-dsDNA IgA2 and IgA2+ B cells as a biomarker for response to Belimumab in SLE. Read in @cp-cell.bsky.social journal - Cell Reports Medicine.

www.nihr.ac.uk/story/strati... a big thank you to the lupus specialists and their patients who made this research possible

STRATIFY lupus is a newly funded precision medicine biomarker enrichment trial funded by @versusarthritis.bsky.social and @nihr.bsky.social with support from @glaxosmithkline.bsky.social in collaboration with @shipam.bsky.social & many UK lupus specialist centres. Will start recruitment early 2026.